<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <title>Clinicians | LiquidMammo™</title>
  <meta name="viewport" content="width=device-width, initial-scale=1" />

  <meta name="description"
        content="Information for clinicians about LiquidMammo™, a microRNA-based supplemental screening test developed to complement breast cancer detection, especially in dense breasts." />

  <!-- Stylesheet -->
  assets/css/styles.css
  favicon.png
</head>

<body>

<!-- ======================================
     MINIMAL HEADER (← Home)
======================================= -->
<header class="container">
  <nav>
    index.html← Home</a>
  </nav>
</header>


<!-- ======================================
     MAIN CONTENT
======================================= -->
<main class="container">

  <h1>Information for Clinicians</h1>

  <!-- Overview -->
  <section class="section-tight">
    <p>
      LiquidMammo™ is a supplemental, non‑invasive <strong>microRNA‑based liquid biopsy</strong> designed
      to strengthen breast‑cancer screening performance — particularly in
      <strong>dense‑breast populations</strong> where mammographic sensitivity is reduced.
    </p>

    <p class="notice" style="margin-top:14px;">
      LiquidMammo is currently being developed as a
      <strong>CLIA Laboratory Developed Test (LDT)</strong>. It is not yet FDA‑cleared or FDA‑approved.
    </p>
  </section>


  <!-- Why clinicians use it -->
  <section class="panel-light section-tight">
    <h2>Why consider a supplemental molecular test?</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:18px;">

      <div class="card-mini">
        <h4>Improved assessment in dense breasts</h4>
        <p class="small">
          Mammographic sensitivity may fall to ~61% in BI‑RADS D tissue. Molecular signal is density‑independent.
        </p>
      </div>

      <div class="card-mini">
        <h4>Non‑invasive & easy to add</h4>
        <p class="small">
          A routine blood draw — no radiation, no compression, minimal patient burden.
        </p>
      </div>

      <div class="card-mini">
        <h4>Supports clinical decision‑making</h4>
        <p class="small">
          Provides complementary biological information to guide follow‑up, escalation, or imaging selection.
        </p>
      </div>

    </div>
  </section>


  <!-- Biological rationale -->
  <section class="section-tight">
    <h2>Biological rationale</h2>
    <p>
      <span class="scientific-term">microRNAs</span> regulate gene expression across oncogenic pathways,
      including proliferation, immune modulation, DNA repair, and metastatic signaling.
      Their stability in blood and early dysregulation make them suitable biomarkers for screening support.
    </p>
  </section>


  <!-- How the test works -->
  <section class="section-tight">
    <h2>How the test works</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:18px;">

      <div class="card-mini">
        <h4>1 — Order through your practice</h4>
        <p class="small">The test is clinician‑ordered, like routine lab assays. Phlebotomy in‑clinic or via partner labs.</p>
      </div>

      <div class="card-mini">
        <h4>2 — Laboratory microRNA analysis</h4>
        <p class="small">
          Plasma is processed under controlled SOPs. A tumor‑associated <span class="scientific-term">microRNA</span>
          signature is quantified and analyzed.
        </p>
      </div>

      <div class="card-mini">
        <h4>3 — Clinician‑ready report</h4>
        <p class="small">
          You receive a structured report including classification, density‑contextual interpretation,
          and recommendations.
        </p>
      </div>

    </div>
  </section>


  <!-- Ideal use cases -->
  <section class="panel-light section-tight">
    <h2>Ideal patient populations</h2>

    <ul class="list-tight">
      <li>Women with <strong>dense breasts</strong> (BI‑RADS C or D).</li>
      <li>Patients with elevated risk or family history.</li>
      <li>Patients who defer mammography due to anxiety, pain, or discomfort.</li>
      <li>Women under 50, where dense tissue is more common.</li>
      <li>Patients needing <strong>more frequent monitoring</strong> between imaging intervals.</li>
    </ul>
  </section>


  <!-- Interpretation -->
  <section class="section-tight">
    <h2>Interpreting results</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:18px;">

      <div class="card-mini">
        <h4>Negative / Low‑risk</h4>
        <p class="small">
          Suggests no microRNA signature consistent with known cancer‑associated patterns.
          Continue guideline‑directed screening.
        </p>
      </div>

      <div class="card-mini">
        <h4>Positive / Elevated signal</h4>
        <p class="small">
          Indicates microRNA changes associated with tumor biology. Consider further imaging
          (diagnostic mammography, ultrasound, MRI).
        </p>
      </div>

    </div>

    <p class="small" style="margin-top:10px;">
      Results should always be interpreted alongside clinical history, density, and imaging.
    </p>
  </section>


  <!-- Safety & compliance -->
  <section class="panel-light section-tight">
    <h2>Safety, quality, and compliance</h2>

    <div class="grid" style="grid-template-columns:repeat(auto-fit,minmax(260px,1fr)); margin-top:18px;">

      <div class="card-mini">
        <h4>CLIA environment</h4>
        <p class="small">
          Testing is performed in a certified CLIA laboratory under strict SOPs, QC steps, and proficiency testing.
        </p>
      </div>

      <div class="card-mini">
        <h4>Sample integrity</h4>
        <p class="small">
          Stabilized plasma collection ensures reproducibility. Chain‑of‑custody safeguards traceability.
        </p>
      </div>

      <div class="card-mini">
        <h4>Privacy & security</h4>
        <p class="small">
          All patient data are de‑identified for analysis and processed under HIPAA‑aligned workflows.
        </p>
      </div>

    </div>
  </section>


  <!-- Enrollment -->
  <section id="enroll" class="section">
    <h2>Clinician enrollment</h2>

    <p>
      We are onboarding a limited number of clinical partners for validation and early access.
      Practices serving dense‑breasted and under‑screened populations are encouraged to inquire.
    </p>

    <div style="margin-top:18px; display:flex; gap:12px; flex-wrap:wrap;">
      contact.html#cliniciansRequest Enrollment</a>
      patients.html#patientsPatient Information</a>
    </div>
  </section>

</main>


<!-- ======================================
     FOOTER
======================================= -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br />
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC,
        and operates out of LabCentral in Cambridge, MA.
      </p>
    </div>

    <div class="footer-logo" style="justify-content:flex-end; text-align:right;">
      assets/logos/multiomics-logo.png
      <div class="footer-note" style="line-height:1.2">
        Developed by<br />MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    privacy.htmlPrivacy & Compliance</a> •
    contact.htmlContact</a>
  </div>
</footer>

</body>
</html>
